LSTA Lisata Therapeutics, Inc.

-

Lisata Therapeutics Reported Earnings

Friday, November 13, 2026 · 12:00 AM ET

Lisata Therapeutics (LSTA) reported a loss of $0.73 per share on revenue of $0.00 million for the third quarter ended September 2026. .

Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases.

Earnings Whisper Grade —
Power Rating—
Reported Earnings
($0.73)
Earnings Whisper®
—
Consensus Estimate
—
Earnings Surprise
Earnings Growth-49.0 %
Reported Revenue
—
Revenue Estimate
—
Revenue Surprise
Revenue Growth—